Andrew Crockett, KalVista CEO
KalVista ends a PhII study early after patients suffer severe and life-threatening side effects
KalVista took a beating Tuesday after announcing it would scrap a Phase II trial for one of its experimental drugs.
The biotech said in an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
